Recent advances in cancer treatment have increasingly focused on harnessing the immune system's power. Emerging immunotherapy approaches that activate natural killer (NK) cells, a crucial component of our innate immune defence, are showing promising results in clinical trials and treatment protocols for various cancer types, including bladder cancer.

Unlike traditional chemotherapy, these innovative treatments aim to enhance the body's defences without the severe side effects often associated with conventional cancer treatments. Patients receiving these immune-activating therapies can be treated on an outpatient basis, potentially avoiding the debilitating impacts of traditional chemotherapy.

While medical interventions continue to advance, research also points to several natural methods for enhancing immune function:
Sleep: Adequate sleep is crucial for the replenishment of NK cells
Sunlight: Exposure to sunlight, particularly certain red wavelengths, may help stimulate immune function
Diet: Avoiding processed foods and toxins that can suppress immune function is essential

Studies have demonstrated that certain nutrients and compounds can significantly support NK cell function. For example, curcumin has shown strong evidence of enhancing natural killer cell activity, which is crucial for targeting cancer cells.

Research indicates curcumin boosts NK cell cytotoxicity against cancer cells by modulating immune signalling pathways. It increases the expression of key markers on NK cells, enhancing their ability to target and eliminate tumour cells.

Additionally, curcumin can promote the secretion of interferon-gamma (IFN-γ), amplifying NK cell-mediated anti-tumour effects. When combined with omega-3 fatty acids, curcumin demonstrates synergistic enhancement of NK cell function and protects these cells from degradation in cancer models such as pancreatic and breast cancer.

Researchers worldwide continue to explore immune-activating treatments for various cancer types. Patients interested in exploring these cutting-edge approaches may wish to search clinical trial databases for current studies accepting participants. 
We have no affiliation with the researcher or the host of the YouTube channel; however, we strongly encourage our readers to watch the interview and learn more about their options using these links.

July 2025 Trial News:

Patients and oncologists confronting the challenge of low lymphocyte counts in solid tumours now have a new, proactive option. According to ImmunityBio’s founder, Dr. Patrick Soon-Shiong, “Restoring lymphocyte levels—rather than depleting them—can change the course of disease. We can now offer hope to patients who have exhausted standard options by reversing immune collapse.”

If you, or someone you support, is living with a solid tumour, has failed standard treatments, and is experiencing low ALC, this expanded access initiative may provide the vital support that’s been missing. Please consult your oncology care team for eligibility and further enrollment steps. Meanwhile, please read the free online study support document to better understand what this means in lay terms: Google Doc link

For more details, please refer to ImmunityBio’s official press release on the FDA Expanded Access authorisation: https://immunitybio.com/immunitybio-receives-fda-expanded-access-authorization-for-landmark-treatment-of-lymphopenia-with-anktiva-the-cancer-bioshield-platform-in-patients-with-solid-tumors/

NIH Immunotherapy Trials Info
To find clinical research studies that involve immunotherapy in the USA visit Find NCI-Supported Clinical Trials or call the Cancer Information Service, NCI’s contact center, at 1-800-4-CANCER (1-800-422-6237).
https://www.cancer.gov/about-cancer/treatment/types/immunotherapy

Immunity Bio's Clinic Trial Information Page:
https://immunitybio.com/find-a-trial/

Immunity Bio's 'Expanded Access' Information Page:
https://immunitybio.com/expanded-access/